SynerK Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

SynerK General Information

Description

Provider of biotechnology services intended to advance ribonucleic acid (RNA)-targeted therapies in oncology, vaccine development, and rare diseases. The company's services apply antisense technology to selectively inhibit disease-causing genes associated with genetic abnormalities, enabling patients and healthcare providers to achieve earlier diagnosis, improved treatment precision, and more effective management of cancer and inherited conditions.

Contact Information

Website
www.synerk.cn
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 86 Baker Avenue Extension
  • Suite 320
  • Concord, MA 01742
  • United States
+1 (978)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 86 Baker Avenue Extension
  • Suite 320
  • Concord, MA 01742
  • United States
+1 (978)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SynerK Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 20-Feb-2019 Completed Pre-Clinical Trials
To view SynerK’s complete valuation and funding history, request access »

SynerK Patents

  • 20

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

SynerK Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260167963-A1 Compounds, compositions and methods for reducing mapt (tau) expression Pending 29-Aug-2024
US-20260043027-A1 Linker, compound including linker, method of preparing compound, use of linker, and method of delivering oligonucleotides through linker Pending 01-Aug-2024
WO-2026026959-A1 Linker, compound including linker, method of preparing compound, use of linker, and method of delivering oligonucleotides through linker Pending 01-Aug-2024
AU-2025245819-A1 Nucleic acid targeting inhibin subunit βe and use thereof Pending 27-Mar-2024
US-20250283085-A1 Oligonucleotide terminal phosphate derivatives and method of use Pending 11-Mar-2024 C12N15/113
To view SynerK’s complete patent history, request access »

SynerK Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SynerK Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
C2I Accelerator Accelerator/Incubator Minority
To view SynerK’s complete investors history, request access »

Ready to get started?

Request a free trial

SynerK FAQs

  • When was SynerK founded?

    SynerK was founded in 2018.

  • Where is SynerK headquartered?

    SynerK is headquartered in Concord, MA.

  • What is the size of SynerK?

    SynerK has 2 total employees.

  • What industry is SynerK in?

    SynerK’s primary industry is Drug Discovery.

  • Is SynerK a private or public company?

    SynerK is a Private company.

  • What is SynerK’s current revenue?

    The current revenue for SynerK is .

  • Who are SynerK’s investors?

    C2I Accelerator has invested in SynerK.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process